Cargando…

Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer

Detalles Bibliográficos
Autores principales:	Zheng, Li, Zhu, Yabi, Liu, Yangyang, Ma, Xu, Xu, Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013639/ https://www.ncbi.nlm.nih.gov/pubmed/35307966 http://dx.doi.org/10.1111/1759-7714.14395

Ejemplares similares

Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States
por: Hu, Jia, et al.
Publicado: (2022)

Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
por: Hirose, Toshiharu, et al.
Publicado: (2023)

Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181
por: Muro, Kei, et al.
Publicado: (2021)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first‐line treatment for advanced esophageal cancer
por: Ye, Zhuo‐Miao, et al.
Publicado: (2022)

A phase Ib/II study of fruquintinib in combination with paclitaxel as the second‐line therapy for advanced gastric cancer
por: Zhang, Yang, et al.
Publicado: (2022)

Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer
por: Park, Chan Su, et al.
Publicado: (2022)

Second line of treatment for HER2-positive gastric cancer: an evolving issue
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?
por: Rajappa, Senthil, et al.
Publicado: (2022)

Second-line treatment options in hepatocellular carcinoma
por: Marino, Donatella, et al.
Publicado: (2019)

Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook
por: Jin, Zixian, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Cai, Hongfu, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study
por: Zhan, Mei, et al.
Publicado: (2022)

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)()()()
por: Si, Lu, et al.
Publicado: (2019)

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
por: Kojima, Takashi, et al.
Publicado: (2022)

Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
por: Chiang, Chi-leung, et al.
Publicado: (2021)

Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
por: Trojan, Jörg, et al.
Publicado: (2016)

Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm
por: Haddox, C. L., et al.
Publicado: (2017)

Pembrolizumab-Induced Myasthenic Crisis with HyperCKemia in a Patient with Thymoma
por: Shin, Ji Hye, et al.
Publicado: (2020)

Surgical pulmonary embolectomy – an underestimated treatment option
por: Zieliński, Dariusz, et al.
Publicado: (2022)

Stem cells as an option for the treatment of COVID-19
por: Cuevas-González, Maria Veronica, et al.
Publicado: (2022)

Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
por: Van Cutsem, Eric, et al.
Publicado: (2021)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
por: Ricci, Francesca, et al.
Publicado: (2017)

Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer
por: Huh, So-Young, et al.
Publicado: (2018)

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
por: Franchi, Matteo, et al.
Publicado: (2022)

Aripiprazole as a treatment option for clozapine-induced enuresis
por: Palaniappan, Pradeep
Publicado: (2015)

Circumcision: Viable treatment option for resistant genital warts
por: Neema, Shekhar, et al.
Publicado: (2016)

Current Aspects of Treatment Options of Chronic Sialorrhea in Children
por: Bittmann, Stefan, et al.
Publicado: (2022)

Haloperidol as a treatment option in cannabinoid hyperemesis syndrome
por: Stawinski, Peter, et al.
Publicado: (2022)

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors is the treatment option of previously treated advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
por: Yang, Xiaobo, et al.
Publicado: (2022)

Second‐line treatment options in advanced thymic carcinoma after failure of platinum‐based chemotherapy: A multicenter retrospective study
por: Wang, Yang, et al.
Publicado: (2022)

PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis
por: Zhu, Xinxin, et al.
Publicado: (2021)

Advances in diagnostic and treatment options in patients with fibromyalgia syndrome
por: Recla, Jill M
Publicado: (2010)

Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab
por: Na, Zhenkun, et al.
Publicado: (2017)

Evidence-based review of treatment options for patients with glottic cancer
por: DE VIRGILIO, A., et al.
Publicado: (2012)

Treatment options for myopic CNV - Is photodynamic therapy still relevant?
por: Chew, Milton C, et al.
Publicado: (2014)

Leukotrichia in Stable Segmental Vitiligo: Implication of an Alternate Treatment Option
por: Jee, Hyun Joong, et al.
Publicado: (2014)

Coccygectomy as a Surgical Option in the Treatment of Chronic Traumatic Coccygodynia
por: Ersen, Omer, et al.
Publicado: (2015)

Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis
por: Garnero, Martina, et al.
Publicado: (2018)

Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment
por: Carbillon, Lionel, et al.
Publicado: (2021)

Treatment of immunothrombosis dysregulation: high-dose corticosteroids is not the good option
por: Helms, Julie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9csggod6ib88ehmpjp7ihq7vi8